GlassScriptPhysician profile
Jesus S Moreno
NPI 1033779590
$4,592.43
in general payments reported to CMS, 2019-2025
29 companies · $704 in 2025
The $704 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $609 · 2024: $3,279 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,494 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,494.09 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $711.60 | 2023-2025 | Glassia |
| Astrazeneca Pharmaceuticals LP | $601.62 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $510.27 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $309.79 | 2024 | Dupixent |
| Grifols USA, LLC | $268.44 | 2023-2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $236.65 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.48 | 2024 | Ofev |
| United Therapeutics Corporation | $198.23 | 2023-2024 | Tyvaso |
| Viiv Healthcare Company | $175.77 | 2025 | Cabenuva, Apretude, Dovato |
| Actelion Pharmaceuticals US, INC. | $141.71 | 2023 | Opsumit, Uptravi |
| Genzyme Corporation | $134.68 | 2024 | |
| Harmony Biosciences LLC | $133.38 | 2024 | |
| Baxter Healthcare | $132.92 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $117.45 | 2023-2024 | Tezspire |
| Philips North America LLC | $112.68 | 2024-2025 | (Ae4) Secretion Management, (8874) Incourage, Vest Therapy Und |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $91.33 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $87.32 | 2024-2025 | Acthar |
| Phadia US INC. | $68.05 | 2023-2024 | Immunocap |
| Gilead Sciences, INC. | $47.06 | 2025 | Biktarvy |
| Mylan Specialty L.P. | $42.64 | 2023-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $41.88 | 2024 | |
| Electromed, INC. | $37.36 | 2024-2025 | Smartvest |
| Hikma Pharmaceuticals USA | $36.79 | 2023-2024 | Ryaltris |
| Theratechnologies INC. | $29.78 | 2025 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $29.40 | 2025 | Capvaxive, Pifeltro |
| Bayer Healthcare Pharmaceuticals INC. | $27.72 | 2024 | |
| Pharming Healthcare, INC. | $23.38 | 2023 | Ruconest |
| Pfizer INC. | $23.00 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $18.05 | 2024 | Lumryz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.